Contraction alterations in Brugada syndrome; association with life-threatening ventricular arrhythmias.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 01 2020
Historique:
received: 29 04 2019
revised: 12 06 2019
accepted: 27 06 2019
pubmed: 10 7 2019
medline: 24 11 2020
entrez: 9 7 2019
Statut: ppublish

Résumé

Brugada syndrome (BrS) is characterized by a high risk of sudden cardiac death. The clinical value of deformation imaging in patients with BrS is unknown. We aimed to assess whether echocardiographic speckle tracking parameters differ between: 1) BrS patients and healthy controls, 2) BrS patients with and without life-threatening ventricular arrhythmias. Left ventricle (LV) and right ventricle (RV) longitudinal strain and mechanical dispersion (MD) were derived from echocardiography at inclusion. Clinical and ECG data were retrospectively assessed. A life-threatening ventricular arrhythmia was defined as an aborted cardiac arrest or sustained ventricular tachyarrhythmia. We included 175 BrS patients and 82 controls. LV and RV longitudinal strain were lower (-18.1 ± 2.6% vs. -18.8 ± 2.0%, p = 0.01 and - 24.4 ± 5.4% vs. 25.6 ± 3.7%, p = 0.04), while MD was higher [38 ± 11 ms vs. 33 ± 8 ms, p = 0.001 and 15 (8-25) ms vs. 11 (6-19) ms, p = 0.03] in BrS patients compared to controls. BrS patients who experienced a life-threatening ventricular arrhythmia (n = 19) had higher LV MD compared to those without events (43 ± 11 ms vs. 37 ± 11 ms, p = 0.02). An LV MD ≥40 ms was optimally associated with life-threatening ventricular arrhythmias [odds ratio 4.62 (95%CI 1.58-13.50), p = 0.005]. BrS patients had lower longitudinal strain and more heterogeneous contractions than healthy controls. Furthermore, BrS patients with a history of life-threatening ventricular arrhythmia had more heterogeneous LV contractions than those without. Therefore, LV MD may be a risk marker in BrS and its evaluation in prospective studies is needed.

Sections du résumé

BACKGROUND
Brugada syndrome (BrS) is characterized by a high risk of sudden cardiac death. The clinical value of deformation imaging in patients with BrS is unknown. We aimed to assess whether echocardiographic speckle tracking parameters differ between: 1) BrS patients and healthy controls, 2) BrS patients with and without life-threatening ventricular arrhythmias.
METHODS
Left ventricle (LV) and right ventricle (RV) longitudinal strain and mechanical dispersion (MD) were derived from echocardiography at inclusion. Clinical and ECG data were retrospectively assessed. A life-threatening ventricular arrhythmia was defined as an aborted cardiac arrest or sustained ventricular tachyarrhythmia.
RESULTS
We included 175 BrS patients and 82 controls. LV and RV longitudinal strain were lower (-18.1 ± 2.6% vs. -18.8 ± 2.0%, p = 0.01 and - 24.4 ± 5.4% vs. 25.6 ± 3.7%, p = 0.04), while MD was higher [38 ± 11 ms vs. 33 ± 8 ms, p = 0.001 and 15 (8-25) ms vs. 11 (6-19) ms, p = 0.03] in BrS patients compared to controls. BrS patients who experienced a life-threatening ventricular arrhythmia (n = 19) had higher LV MD compared to those without events (43 ± 11 ms vs. 37 ± 11 ms, p = 0.02). An LV MD ≥40 ms was optimally associated with life-threatening ventricular arrhythmias [odds ratio 4.62 (95%CI 1.58-13.50), p = 0.005].
CONCLUSIONS
BrS patients had lower longitudinal strain and more heterogeneous contractions than healthy controls. Furthermore, BrS patients with a history of life-threatening ventricular arrhythmia had more heterogeneous LV contractions than those without. Therefore, LV MD may be a risk marker in BrS and its evaluation in prospective studies is needed.

Identifiants

pubmed: 31281045
pii: S0167-5273(19)32197-7
doi: 10.1016/j.ijcard.2019.06.074
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

147-152

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Esther Scheirlynck (E)

Department of Cardiology, Universitair Ziekenhuis Brussel, Centrum voor Hart- en Vaatziekten, Brussels, Belgium; Life sciences and Medicine, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: esther.scheirlynck@vub.be.

Sophie Van Malderen (S)

Life sciences and Medicine, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: svmalder@msn.com.

Andreea Motoc (A)

Department of Cardiology, Universitair Ziekenhuis Brussel, Centrum voor Hart- en Vaatziekten, Brussels, Belgium; Life sciences and Medicine, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: andreeaiulia.motoc@uzbrussel.be.

Øyvind H Lie (ØH)

Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Center for Cardiological Innovation, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Institute for Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address: Oyvind.Haugen.Lie@rr-research.no.

Carlo de Asmundis (C)

Department of Cardiology, Universitair Ziekenhuis Brussel, Centrum voor Hart- en Vaatziekten, Brussels, Belgium. Electronic address: carlo.deasmundis@uzbussel.be.

Juan Sieira (J)

Department of Cardiology, Universitair Ziekenhuis Brussel, Centrum voor Hart- en Vaatziekten, Brussels, Belgium. Electronic address: juan.sieira@uzbrussel.be.

Gian-Battista Chierchia (GB)

Department of Cardiology, Universitair Ziekenhuis Brussel, Centrum voor Hart- en Vaatziekten, Brussels, Belgium. Electronic address: jeanbaptiste.chierchia@uzbrussel.be.

Pedro Brugada (P)

Department of Cardiology, Universitair Ziekenhuis Brussel, Centrum voor Hart- en Vaatziekten, Brussels, Belgium. Electronic address: pedro.brugadaiterradellas@uzbrussel.be.

Bernard Cosyns (B)

Department of Cardiology, Universitair Ziekenhuis Brussel, Centrum voor Hart- en Vaatziekten, Brussels, Belgium; Life sciences and Medicine, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: bernard.cosyns@uzbrussel.be.

Steven Droogmans (S)

Department of Cardiology, Universitair Ziekenhuis Brussel, Centrum voor Hart- en Vaatziekten, Brussels, Belgium; Life sciences and Medicine, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: steven.droogmans@uzbrussel.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH